MATINAS BIOPHARMA HOLDINGS I (MTNB) Stock Overview
NYSEARCA:MTNB - US5768103039 - Common Stock
MTNB Key Statistics, Chart & Performance
The current stock price of MTNB is 1.71 USD. In the past month the price increased by 51.33%. In the past year, price decreased by -55.47%.
MTNB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.7 | 368.47B | ||
| AMGN | AMGEN INC | 12.81 | 150.41B | ||
| GILD | GILEAD SCIENCES INC | 14.91 | 143.15B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.21 | 100.83B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.16 | 58.81B | ||
| ARGX | ARGENX SE - ADR | 81.97 | 46.50B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.02 | 40.92B | ||
| INSM | INSMED INC | N/A | 30.88B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.89B | ||
| NTRA | NATERA INC | N/A | 22.95B | ||
| BIIB | BIOGEN INC | 8.87 | 20.81B |
Related stock screener links
About MTNB
Company Profile
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Bedminster, New Jersey and currently employs 3 full-time employees. The company went IPO on 2014-06-03. The firm is focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology. Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 has completed a Phase II encochleated oral amphotericin for cryptococcal meningitis trial (EnACT) study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options.
Company Info
MATINAS BIOPHARMA HOLDINGS I
Suite 302, 1545 Route 206 South
Bedminster NEW JERSEY 07921 US
CEO: Jerome D. Jabbour
Employees: 3
Phone: 19084431860
MATINAS BIOPHARMA HOLDINGS I / MTNB FAQ
What is the stock price of MATINAS BIOPHARMA HOLDINGS I today?
The current stock price of MTNB is 1.71 USD. The price decreased by -0.58% in the last trading session.
What is the ticker symbol for MATINAS BIOPHARMA HOLDINGS I stock?
The exchange symbol of MATINAS BIOPHARMA HOLDINGS I is MTNB and it is listed on the NYSE Arca exchange.
On which exchange is MTNB stock listed?
MTNB stock is listed on the NYSE Arca exchange.
What is MATINAS BIOPHARMA HOLDINGS I worth?
MATINAS BIOPHARMA HOLDINGS I (MTNB) has a market capitalization of 9.49M USD. This makes MTNB a Nano Cap stock.
How many employees does MATINAS BIOPHARMA HOLDINGS I have?
MATINAS BIOPHARMA HOLDINGS I (MTNB) currently has 3 employees.
What are the support and resistance levels for MATINAS BIOPHARMA HOLDINGS I (MTNB) stock?
MATINAS BIOPHARMA HOLDINGS I (MTNB) has a support level at 1.7 and a resistance level at 1.83. Check the full technical report for a detailed analysis of MTNB support and resistance levels.
Should I buy MATINAS BIOPHARMA HOLDINGS I (MTNB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MTNB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MTNB, evaluating the profitability, health, valuation and growth aspects
- MATINAS BIOPHARMA HOLDINGS I (MTNB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MATINAS BIOPHARMA HOLDINGS I (MTNB) Sales and EPS estimates to see what analysts future expectations are.
- MATINAS BIOPHARMA HOLDINGS I (MTNB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MATINAS BIOPHARMA HOLDINGS I (MTNB) Insider and Institutional Ownership to learn about the owners and their transactions.
- MATINAS BIOPHARMA HOLDINGS I (MTNB) Stock Chart to make your own analysis
- MATINAS BIOPHARMA HOLDINGS I (MTNB) Latest news and press-releases to stay up to date.
Does MATINAS BIOPHARMA HOLDINGS I (MTNB) stock pay dividends?
MTNB does not pay a dividend.
When does MATINAS BIOPHARMA HOLDINGS I (MTNB) report earnings?
MATINAS BIOPHARMA HOLDINGS I (MTNB) will report earnings on 2025-11-11.
What is the Price/Earnings (PE) ratio of MATINAS BIOPHARMA HOLDINGS I (MTNB)?
MATINAS BIOPHARMA HOLDINGS I (MTNB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.17).
What is the Short Interest ratio of MATINAS BIOPHARMA HOLDINGS I (MTNB) stock?
The outstanding short interest for MATINAS BIOPHARMA HOLDINGS I (MTNB) is 2.66% of its float. Check the ownership tab for more information on the MTNB short interest.
MTNB Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to MTNB. When comparing the yearly performance of all stocks, MTNB is one of the better performing stocks in the market, outperforming 82.52% of all stocks.
MTNB Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to MTNB. MTNB has a bad profitability rating. Also its financial health evaluation is rather negative.
MTNB Financial Highlights
Over the last trailing twelve months MTNB reported a non-GAAP Earnings per Share(EPS) of -4.17. The EPS increased by 24.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -191.84% | ||
| ROE | -319.51% | ||
| Debt/Equity | 0 |